An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice - a podcast by ReachMD

CME credits: 0.50

Valid until: 28-01-2022

Claim your CME credit at https://reachmd.com/programs/cme/evolving-clinical-landscape-her2-and-her2-mutant-metastatic-nsclc-critical-updates-your-practice/12150/

Targeted therapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC) across a broad range of molecular aberrations. The epidermal growth factor receptor (EGFR), a member of the HER/ErbB family of membrane-bound proteins, was one of the first successful targets in lung cancer, and HER2, another member of the HER/ErbB family, is a valid target in breast and gastric cancers. Yet developing effective HER2-targeted therapy for patients with NSCLC has been difficult, leading some to underestimate the potential of HER2 as a target in NSCLC. Fortunately, recent data suggest that a novel antibody-drug conjugate (ADC) has clinically meaningful activity in HER2-mutated, metastatic NSCLC, and this agent, trastuzumab deruxtecan, has been granted “breakthrough therapy” designation for this use. As important as this finding is, it adds to the volume of data being generated in lung cancer every day, and many oncologists report feeling overwhelmed by lung cancer advances. This situation is only exacerbated as the COVID-19 pandemic taxes healthcare professionals and systems alike. Oncologists, therefore, need education about the latest advances in the targeted treatment of NSCLC with HER2 aberrations, delivered in a format and location that makes the education timely, succinct, and accessible to close these gaps.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD